Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Resonance Health (RHT) appoints Mitchell Wells to the role of Managing Director to lead the company
  • Mr Wells succeeds Alison Laws, who will hand over the reins as CEO of Resonance Health on Friday, July 2, 2021
  • The new Managing Director will take the helm as it markets its scalable, AI-based medical devices, along with a pipeline of commercially focussed research and development projects
  • Resonance Health was trading flat at 15.5 cents at 1:15 pm AEST

Resonance Health (RHT) has welcomed a new Managing Director to lead the company.

Mitchell Wells will transition from his current role as Executive Director to Managing Director.

Mr Wells first joined the Resonance team in April 2017, where he provided strategy, contract and corporate advisory services before joining the Board of Directors in early 2018, serving as a director and consultant.

In his role, Mr Wells has been involved in the company’s commercial contracts and negotiations, initiatives and projects, including the regulatory frameworks required to operate as a manufacturer of medical devices.

Mr Wells succeeds Alison Laws, who will hand over the reins as CEO of Resonance Health on Friday 2 July 2021. Following this, Ms. Laws will provide consultancy services to the company.

“I have worked with Mitchell since 2017 and I’m delighted that he is transitioning into the role of Managing Director of Resonance Health,” Outgoing CEO of Resonance Health, Alison Laws said.

“The company will progress its strategy for a heightened sales focus and further acceleration of our high impact late-phase R&D projects, with greater engagement with the capital markets.

“Mitchell is very well suited to this next phase, and I look forward to continuing my productive relationship with him, as a consultant to Resonance Health,” she said.

The new Managing Director will take the helm as it markets its scalable, AI-based and recently regulatory cleared medical devices, along with a pipeline of very high-impact late-phase commercially focused research and development projects.

Resonance Health was trading flat at 15.5 cents at 1:15 pm AEST.

RHT by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.